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Abstract 
Purpose: Idiopathic basal ganglia calcification (IBGC) is a rare, intractable disease with unknown etiology. IBGC3 is 
a familial genetic disease defined by genetic mutations in the major causative gene (SLC20A2). People with IBGC3 
experience distress from the uncommon nature of their illness and uncertainty about treatment and prognoses. The 
present study aimed to describe the lives and illness of people with IBGC3.
Methods: Participants were recruited from patients aged 20 years or older enrolled in a genetic study, who were 
diagnosed with IBGC3 and wanted to share their experiences. In-depth semi-structured interviews were conducted 
with six participants. Interviews were conducted between December 2012 and February 2014, and were recorded 
and transcribed verbatim. Qualitative data analysis was performed to identify categories and subcategories. Efforts 
were made to ensure the credibility, transferability, dependability, conformability, and validity of the data.
Results: Six thematic categories, 17 subcategories, and 143 codes emerged. The six categories were: (1) Frustration 
and anxiety with progression of symptoms without a diagnosis; (2) Confusion about diagnosis with an unfamiliar dis-
ease; (3) Emotional distress caused by a genetic disease; (4) Passive attitude toward life, being extra careful; (5) Taking 
charge of life, becoming active and engaged; and (6) Requests for healthcare.
Conclusions: The qualitative data analysis indicated a need for genetic counseling, access to disease information, 
establishment of peer and family support systems, mental health services, and improvement in early intervention and 
treatment for the disease.
Keywords: Idiopathic basal ganglia calcification (IBGC), Primary familial brain calcification (PFBC), Fahr disease, 
Narrative, Qualitative research
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Background
Idiopathic basal ganglia calcification (IBGC), also called 
Fahr disease, is a rare and intractable disease. It shows 
abnormal deposits of calcium in the basal ganglia, the 
dentate nuclei of the cerebellum, the pulvinar thalami, 
and subcortical white matter (Manyam 2005). For a 
diagnosis of IBGC, other known causes of calcification, 
including metabolic, infectious, toxic, or traumatic causes 
should be excluded (Bonazza et al. 2011). The clinical fea-
tures of IBGC include parkinsonism, cerebellar symp-
toms, cognitive impairment, psychosis, seizures, and 
chronic headache. Patients may also be asymptomatic.
Historically, more than 37 names had been used to 
describe the disease. Recently the designation “primary 
familial brain calcification (PFBC)” has been proposed in 
opposition to ‘secondary’ and on the basis of family his-
tory (Sobrido et al. 2014). The designation and classifica-
tion from the genetic background are needed for further 
study to clarify the pathophysiology. With vague criteria 
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and an unknown etiology, Fahr disease was a blind spot 
in medical care. The discovery of the mutations in the 
gene SLC20A2 which cause IBGC3 was a turning point 
in understanding the disease’s pathophysiology. Recently, 
other causative genes have been reported, especially in 
familial IBGC (FIBGC) cases, and classified as IBGC 3–6 
(Wang et al. 2012; Yamada et al. 2014; Nicolas et al. 2013; 
Keller et al. 2013: Legati et al. 2015). The phenotypes are 
thought to not necessarily be correlated with the geno-
types (Nicolas et al. 2015). In most patients, FIBGCs are 
considered to be autosomal dominantly inherited.
Even today, IBGC itself is not well known to the general 
public. There is also insufficient information available via 
social networking or similar agencies to further under-
standing of the disease. Therefore, despite a diagnosis 
and some medical information provided by their doctors, 
people with a diagnosis of IBGC may be upset by an unfa-
miliar genetic disease, and experience despair. To date, 
no clinical research on the mental health needs of people 
with IBGC has been available. FIBGC type 3 is the most 
common type of FIBGC worldwide, including in Japan 
(50  % of all cases) (Yamada et  al. 2014). Therefore, this 
study was conducted to allow definitive examination of a 
homogeneous sample of patients with IBGC3, and pro-
vide an initial profile of their self-reported social, medi-
cal, and psychological challenges. Patients with IBGC3 
were interviewed after informed consent was obtained. 
We conducted a qualitative analysis of the interview data, 




In our ongoing genetic study, ten patients had been diag-
nosed with IBGC3. Participants were recruited from 
those patients who were over 20 years of age and wanted 
to talk about their experiences. Six patients partici-
pated in the present study, two females (F1 and F2) and 
four males (M1–4). Clinical features of the participating 
patients are shown in Table 1.
The genetic mutations of five patients (T115M, S637R, 
T115M, S637R and R467S) have been identified in a pre-
vious paper (Griffiths et al. 2007). In addition to the data 
reported in the previous paper (Griffiths et al. 2007), the 
genetic mutation of M1 was confirmed to be identical 
to that of his mother (F1). At the time of interview, par-
ticipants’ ages ranged from the late 20s to early 70s. The 
interval since being informed of their diagnosis varied 
from a few months to 3 years. M1 and M2 are sons of F1 
and F2, respectively. M1, M2, and M3 were not married. 
All participants except M2 had symptoms. Although 
M2 felt well, his mother (F2) recommended he go to a 
hospital.
A new nonsense mutation, c.1848 G>A, p.(Trp616*), 
inducing a stop codon in exon 11 of SLC20A2 and result-
ing in a putative truncated protein, was discovered in 
M4 (III-2, in Fig.  1a), a 29-year-old man. He had suf-
fered from paroxysmal kinesigenic choreoathetosis 
(PKC) and had taken carbamazepine since age 13 years. 
His brain computed tomography (CT) images revealed 
a typical pattern of calcification in the bilateral globus 
pallidus, caudate nuclei, putamen, pulvinar thalami, 
dentate nuclei, and subcortical white matter (Fig.  1b). 
He obtained information about his and his family mem-
bers’ diseases from a doctor in China: his uncle (II-2), his 
cousin (III-1), and his grandfather (I-2) had all suffered 
from calcification in the brain (Fig. 1c), but the mutations 
causing PKC had not been found in his genetic analysis. 
He was taken to the present authors’ hospital by his Japa-
nese wife for a medical examination. The medical exami-
nation revealed that the PKC was well controlled, but he 
experienced headaches when he had a cold.
Interview records
Participant interviews were conducted between 
December 2012 and February 2014. Interviews were 
performed in a quiet, closed room in a hospital or 
hotel, with no other person present. Participants were 
interviewed once, with interviews lasting 50–90  min. 
The six semi-structured interviews were based on a 
loose structure comprising open-ended questions, and 
were conducted according to the methodological orien-
tation of Sandelowski (2000). Interviews were face-to-
face and performed by a professional interviewer who 
first introduced herself and obtained written informed 
consent.
Each interview was recorded with a digital voice 
recorder. The protection of participants’ privacy was 
paramount. The interviewer encouraged participants to 
speak about their experiences as freely as possible. The 
interview questions were: “How did you find out about 
your disease?”; “What did you think when you heard the 
diagnosis of your disease?”; “How do you feel about your 
disease at present?”; “How do you feel about your fam-
ily after hearing your diagnosis?”; “Is there anything you 
have learned through your experiences?”; and “What do 
you expect in terms of medications and medical care?”
Analysis
All statements made by participants in the interviews 
were recorded and fully transcribed. The credibility and 
transferability of interview texts were checked by two 
researchers. The transcribed texts were analyzed using 
qualitative data analysis software, MAXQDA10 (VERBI 
Software, Berlin, Germany). First, all data were carefully 
interpreted and the transcriptions divided into partitions 
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according to content. Each chunk was coded with defi-
nite terms using the words from the participant’s narra-
tive. In this procedure, chunks were rearranged over the 
time course. Next, codes were summarized by a suitable 
concept and named with representative terms (subcat-
egorization). All data were examined again carefully and 
the content of codes and subcategories were re-exam-
ined. Finally the subcategories were summarized in wider 
concepts and named according to key characteristics 
(categorization). To ensure the validity of the data inter-
pretation, the results were checked by the participants 
and other members of the research team.
Results
Six categories, 17 subcategories, and 143 codes were 
extracted: categories are shown using () and subcatego-
ries are shown by ≪≫ (Table 2). In terms of coding the 
six categories, all participants reported similar experi-
ences and impressions. For example, a participant with 
some symptoms had consulted a doctor, but felt more 
anxious about the disease progression because the doctor 
did not provide a proper diagnosis. When the participant 
was finally informed of his diagnosis with an unfamil-
iar disease, he was upset. In addition, he felt distressed 
by hearing the disease was a genetic disease and feared 
personality changes due to cryptogenic abnormalities. He 
also wished for a better medical system and the opportu-
nity to ask questions of medical doctors.
The six categories were: (frustration and anxiety with 
progression of symptoms without being diagnosed), 
(confusion about diagnosis with an unfamiliar disease), 
(emotional distress caused by a genetic disease), (passive 
attitude toward life, being extra careful), (taking charge 
of life, becoming active and engaged), and (requests for 
healthcare).
In addition, we reported participants’ “questions for 
medical doctors”. Each category and corresponding sub-
categories are discussed below (Table 2).
Category 1: (frustration and anxiety with progression 
of symptoms without being diagnosed)
Two patients, M3 and M4, who had shown symptoms 
of PKC reported that they ≪had not felt any physical 
abnormality in their teens≫. However, in their 20s, they ≪were recommended to consult doctors by their friends 
and parents≫ because of gait disturbance and toppling 
falls. Other participants, F1 and F2, were also recom-
mended by their husbands and daughters to consult doc-
tors because of forgetfulness and articulation disorders. 
F1 and F2 had suffered from the disease for 2–13 years, 
and reported they ≪had obsessed with anxiety about the 
unknown disease and progression of their symptoms≫.
Table 1 Clinical features of study participants (n = 6)
F 1 F 2 M 1 M 2 M 3 M 4
Mutation c.344C>T c.1909A>C c.344C>T c.1909A>C c.1399C>T c.1848G>A
T115M S637R T115M S637R R467X T616X
Participant information
 Place of residence Hokkaido island The main island Hokkaido island The main island Shikoku island Shanghai in China
 Age at onset 
(years)
58 60 46 Unknown 15 13
 Age at detection 
of calcification 
(years)
60 60 50 22 23 25
 Age at diagnosis 
of IBGC3 (years)
69 64 50 22 26 26
 Onset symptom Dysarthria Dysarthria Easy to anger – PKC PKC
Interview
 Age at interview 
(years)
72 66 50 22 26 28
 Symptoms at 
interview




Unstable Cramp Headache, unstable
Family information
 Other patients in 
the family
Her son and five 
relatives
Her son His mother and five 
relatives
His mother His mother Three relatives
References II-1 in F3 Case 3, 
Yamada et al. 
(2014)
III-1 in F1 Case 1, 
Yamada et al. 
(2014)
II-1 in F3,  
Yamada et al. 
(2014)
II-2 in F1,  
Yamada et al. 
(2014)
Case 5,  
Yamada et al. 
(2014)
Figure 1
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“I was told ‘you are limping’ by my colleagues in my 
work place. I knew that others had recognized my 
disability. I tried to repeat the action of ‘stop and 
move’ but I felt paralysis about once per 100 times. 
Before that I had not paid attention to it, but I 
decided to consult an orthopedist.” (M3)
Category 2: (confusion about diagnosis with an unfamiliar 
disease)
Participants M4 and F2 had taken proactive action to 
seek a clear diagnosis. F2 was recommended to consult 
a doctor at a university hospital by an acquaintance with 
similar symptoms. M4 had obtained information on the 
disease via the Internet and consulted a medical doctor 
specializing in neurology at Gifu University Hospital. 
They had been examined and informed of their IBGC3 
diagnosis. Both M4 and F2 mentioned they felt fear 
about the progression of the disease and ≪got upset 
when they heard the diagnosis was a genetic and intrac-
table disease≫. M2, who was thought to be presympto-
matic ≪calmly understood the situation afterwards≫. 
M2 (asymptomatic) was the only participant who ≪did 
not check because there was fear about knowing≫. 
The other male participants, M1, M3, and M4, were 
confused on hearing their diagnosis and reported that 
they ≪were not able to obtain sufficient information 
about the disease on the Internet and were not satisfied 
with the information≫, in which the symptoms varied 
widely.
“Before I was told the name of the disease, I had 
been told I suffered from a genetic intractable dis-
ease. I was shocked and my head went blank. I knew 
the name ‘Fahr disease’ when I saw the name on the 
examination paper written by another doctor.” (F2)
“At that time I was a little bit shocked. I was really 
shocked. Because I knew that disease. I knew how 
it is going to be…But I have to shout.” (Spoken in 
English by M4)
Category 3: (emotional distress caused by a genetic 
disease)
Four younger patients, M1, M2, M3, and M4, experi-
enced great distress when they realized the disease was 
a genetic disease. M1, M2, and M3 reported that they ≪tended to avoid contacting their brothers and sisters, 
who did not have the same symptoms≫. M2 and M3 had 
tried to cover up the situation with their work colleagues, 
although they ended up ≪confessing to their supervi-
sors about contracting the disease to account for their 
absences to consult doctors≫.
M3, who had a fiancée, and M4, who was married, 
reported having ≪concerns for marriage and child-
birth≫. M3 mentioned that his fiancée understood his 
situation and disease, but her parents and relatives were 
strongly opposed to their marriage. They had seriously 
considered the possibility of adopting children.
“I started to worry about the future. Maybe we are 
going have kids, what if, what if going to have a kid…
Ah, yes. I changed to a healthy life style. I’m having 
healthy diet…I had talked with my wife a couple of 
times during this half year. From my side, I think…
I’d still like to, to have a child, somehow.” (Spoken in 
English by M4)
Fig. 1 a Family tree of Case M4. The arrow indicates the index sub-
ject. Filled symbols represent family members affected by calcification. 
b Computed tomography images of Case M4. Typical calcification 
was seen in bilateral basal ganglia, dentate nuclei in the cerebellum, 
and the subcortical white matter. c DNA sequence electropherogram 
showing the mutations [c.1848 G>A, p.(Trp616*), inducing a stop 
codon in exon 11] in the patient (M4). Letters in red indicate mutated 
sequences
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Category 4: (passive attitude toward life, being extra 
careful)
Symptoms of IBGC such as forgetfulness, headache, and 
clumsiness were not easily recognized without the par-
ticipants’ acknowledging them, even by their families. 
Participants tended to hide their symptoms and were 
careful not to make mistakes or cause trouble for others. 
They did not show their disabilities caused by the disease. 
This made participants more introverted and reserved. 
F2 tended to drive the car on the center of the road. M1 
could not write letters when he was tired. M4 and M1 
tended to have passive attitudes because of their fear of 
what may happen.
“Somehow I worry about the disease when I drive 
a car. When my car was driven in the center of the 
road, I felt there was something wrong with me…I’ve 
been be very careful in driving.” (F2)
“I have stones in my brain, haven’t I?…just like 
stones in tofu (soybean curd). If I shake my head 
strongly, moving stones would damage the tofu…
Then I always try not to shake my head in my life.” 
(M4)
Most participants were concerned about the disease 
and tried to manage the situation. F1 mentioned that she ≪dealt with things while embracing the anxiety≫. Par-
ticipants reported they ≪had experienced troubles in life 
that others could not know≫. M2 remarked he tried to 
forget the disease. In contrast, some participants tried 
to behave proactively. M2 and M4 were willing to have 
regular check-ups. M3 wanted to buy medical insurance 
before onset of the disease.
Category 5: (taking charge of life, becoming active 
and engaged)
Participants ≪were willing to communicate with other 
patients with the same disease≫ and get useful infor-
mation from others. They felt frustrated with the lack 
of medical information. F2, M1, M2, M3, and M4 were 
willing to take a part in a community for patients with 
IBGC. M1 also wanted to get into an Internet com-
munication forum. In contrast, F1 who had taken a 
part in a community for patients once before, was not 
interested in participating again because she found 
that others only talked about their concerns. M2 and 
M3 had mixed feelings: they wanted to talk about their 
situation with others, but not those with more severe 
symptoms.
“I think that the symptoms vary widely. Perhaps 
my symptoms seem to be mild. If other patients 
have more severe symptoms than mine, I’m afraid 
that it would hurt others’ feelings. This means that 
I would have to watch what I say.” (M3)
Some participants changed their perspective on their 
lives after being diagnosed with a rare, intractable dis-
ease. M4 mentioned he ≪recognized that his life was 
not only for himself≫ and began to pay more attention 
to his health to prevent the disease progression, not only 
for himself but also for his wife. M2 and M3 understood 
Table 2 The coding tree
Categories Subcategories
Frustration and anxiety with progression of symptoms without being 
diagnosed
Had not felt any physical abnormality in their teens
Were recommended to consult doctors by their friends and parents
Had obsessed with anxiety about the unknown disease and progression of 
their symptoms
Confusion about diagnosis with an unfamiliar disease Got upset when they heard the diagnosis was a genetic and intractable 
disease
Calmly understood the situation afterwards
Did not check because there was fear about knowing
Were not able to obtain sufficient information about the disease on the 
Internet and were not satisfied with the information
Emotional distress caused by a genetic disease Tended to avoid contacting their brothers and sisters, who did not have the 
same symptoms
Confessing to their supervisors about contracting the disease to account 
for their absences to consult doctors
Concerns for marriage and childbirth
Passive attitude toward life, being extra careful Dealt with things while embracing the anxiety
Had experienced troubles in life that others could not know
Taking charge of life, becoming active and engaged Were willing to communicate with other patients with the same disease
Recognized that life was not only for oneself
Requests for healthcare Specialized doctors and hospitals should be increased
medical financial supports must be provided
Expected enactment of laws allowing euthanasia
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that the disease had derived from their mother but did 
not blame anyone for the disease.
Category 6: (requests for healthcare)
Some patients mentioned a desire for an improved medi-
cal system. F2, M3, and M4 felt that ≪specialized doctors 
and hospitals to deal with IBGC should be increased≫ 
because they had experienced several incorrect diagno-
ses from unspecialized doctors. All participants insisted ≪medical financial support must be provided≫. For 
example, F2 had finally quit the job she had been reem-
ployed in when she was injured by a toppling fall, and M1 
was excluded from night shifts because of less achieve-
ment in his job. In addition, M1, who had large calcifi-
cation on his CT images, ≪expected enactment of laws 
allowing patients to practice euthanasia in Japan≫.
Participants were also asked whether they had some 
questions for doctors. Table  3 presents a list of these 
questions. In particular, participants wanted to know 
the relationship between headaches and the disease, and 
about calcification of the blood vessels and in the brain.
Discussion
Qualitative research involving patients’ perspectives of 
their illness can generate new insights for medication, 
mental health care, and nursing, even when the number 
of patients is relatively small (Sandelowski 2000). Quali-
tative studies have been performed for major diseases 
such as cancer (Ziebland and McPherson 2006), rheu-
matoid arthritis (Hilton et  al. 2009), and motor neuron 
disease (Newman et al. 2009; Locock et al. 2009; Caputo 
2014). However, relatively few quantitative studies have 
been conducted on rare diseases, especially cancers 
(Griffiths et  al. 2007; Witham et  al. 2008), and there is 
little research on rare neurological diseases (Jaeger et al. 
2015; Purcell et  al. 2015). In Huntington’s disease, for 
example, patients’ quality of life, and the experiences and 
perspectives of family carers have been studied (Aubee-
luck and Buchanan 2007; Williams et al. 2009; LoGuidice 
and Hassett 2005).
To date, 230 patients with IBGC in Japan have been 
enrolled in our genetic study. Although the etiology 
of IBGC was previously unknown, the mutations of 
SLC20A2 encoding type III sodium-dependent phos-
phate transporter type III (PiT)-2 were reported in 2012 
by Chinese researchers (Wang et  al. 2012). Thereafter, 
several groups worldwide (including ours) have demon-
strated that the mutation of SLC20A2 is a major cause 
of familial IBGC (Wang et al. 2012; Yamada et al. 2014; 
Hsu et  al. 2013). As IBGC3 (SLC20A2) is a genetically 
definite category and central to the syndrome, the 
results of clinical studies on IBGC3 are important and 
may be applied well beyond the confines of the present 
study to other types of IBGC. This study revealed three 
key points.
First, the qualitative analysis of the patients’ narra-
tives clarified their worries and attitudes toward their 
lives. They had similar thought processes, including anxi-
ety about the clinical features and future progress of the 
disease, particularly about observing their mothers and 
relatives, after they were told that the disease was famil-
ial and hereditary. They worried about marriage and 
childbirth and were anxious about needing full care in 
the future. Their attitudes had become introverted and 
focused on keeping their good health and not causing 
trouble to surrounding people.
Second, their questions and worries about the disease 
changed throughout their experiences in dealing with 
the disease. In the early stages, they could not get enough 
information through books or the Internet to understand 
the disease, and wanted to obtain information directly 
from medical doctors. However, they were told they suf-
fered from a disease with an unfamiliar name and were 
at a loss for adequate information. For example, one par-
ticipant (M1) thought he should not shake his head. The 
more correct information participants received, the more 
positive their attitudes were. Gradually, they were able 
to change their attitudes about their disease to be more 
positive.
Third, this study highlighted the psychological dis-
tress participants experienced because there is no medi-
cal cure for the disease. As they had been told that the 
disease was intractable, participants tended not to think 
about the disease. This coping method was similar to the 
behavior of patients with neurological intractable dis-
eases reported by Higaki and Suzuki (2002). In addition, 
one participant wanted the option of euthanasia because 
the disease was not curable and he felt that death was 
imminent. Although he wanted to live a significant life, 
he experienced agony about his death.
Table 3 Participants’ questions for medical doctors
What is the incidence rate of the disease?
Has the disease existed for a long time or is it a modern disease?
What is the most common symptom?
Is the occipital headache derived from the disease?
Do some people with calcification in the brain live without symptoms?
Is the intracranial pressure increased with the enlargement  
of calcification?
Is the brain damaged with strong movement because the brain  
is soft and calcification is hard?
Can thrombosis occur because calcification is seen in the blood vessels?
What is the proper time interval for the medical consultation?
How much does it cost for the full medical examination?
How is research for treatment progressing?
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Throughout the reported experiences of living with a 
familial intractable disease, we found some participants 
changed their minds about their lifestyles. They realized 
that their lives were not only for themselves, and would 
undergo regular check-ups and pay more attention to 
their health for their spouses and families. Kukinaka et al. 
(2013) reported similar feelings in patients with familial 
amyloid polyneuropathy.
Finally, this study has a key limitation. IBGC is a rare 
disease and the number of participants was therefore 
small. Generally, most patients with IBGC are sporadic 
and heterogeneous. We focused on genetically identified 
homogenous IBGC3. Although our conclusions are not 
meant to apply for all patients, those will be a foundation 
for the care of patients with IBGC or rare neurological 
diseases.
Proposals for medical care for patients with IBGC3
Based on the present analysis, we identified three medi-
cal care proposals for patients with IBGC3.
Genetic counseling and mental health support
A genetic counseling and mental health support system 
should be established. Most patients with IBGC are wor-
ried about their genetic disease. According to the guide-
line for Prion disease in Japan, it is important for medical 
staff to understand patients’ and their families’ feelings, 
including anger, sadness, agony, and anxiety. Patients 
with IBGC and their families need support from medical 
staff to overcome psychological difficulties. We propose 
that medical staff consider the psychological processes of 
patients’ and their families’ and accept their feelings. This 
may help patients and their families to develop their abil-
ity to control and manage their feelings.
In addition, medical staff should identify methods to 
reduce patients’ anxiety about incurable diseases, to help 
prevent patients obsessing over the disease. Medical 
staff could educate patients about methods to decrease 
anxiety. Monat and Lazarus (1991) reported that a com-
bination of direct medical treatments and psychologi-
cal and emotional treatments is more effective than one 
treatment alone. Medical staff should therefore support 
patients both practically and psychologically.
In further discussion, the organization of genetic 
counselling deeply depends on how the health system 
is organized, reimbursed and how clinical genetics is 
integrated.
Questions and answers for medical information and early 
intervention
From a patient’s perspective, the most important con-
siderations for medical staff are to prevent misunder-
standings about the disease because of insufficient 
information, and provide adequate answers to their ques-
tions. “Q and A” handouts for patients should be updated 
regularly. In the early stages, medical staff should offer 
regular check-ups and instructions to patients; this is 
particularly recommended to improve the medical care 
for patients with IBGC3.
Patient support
The participants in our study tended to associate with 
other patients. Hotta and Hozumi (2012) reported that 
counseling and supporting systems were most desired by 
solitary (non-familial) patients with IBGC. Unlike other 
diseases, patients with rare and intractable diseases may 
be widespread and find it difficult to get together. In this 
case, medical staff should establish a patient association 
meeting or similar organized community, and perhaps 
use online platforms such as social networking to provide 
opportunities for patients to share information, anxiety, 
and feelings. Medical staff should observe the transitions 
of patients’ symptoms and feelings, support information 
exchanges to reduce feelings of isolation among patients 
with the same disease, and promote any necessary rear-
rangement of their life plans.
Conclusion
This qualitative analysis of the narratives of patients with 
IBGC3 clarified their worries and attitudes towards their 
lives, the psychological changes that accompanied the 
progression of the disease, and their psychological dis-
tress as a result of insufficient medical information. We 
found that some patients were able to positively change 
their minds about living. This study also indicated a spe-
cific direction for the future medical care of patients with 
IBGC3. Patients highlighted the need for genetic coun-
seling, mental health support, medical information “Q 
and A,” early intervention, and a patient community.
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